作者
Wei-Fan Hsu, Hung-Wei Wang, Cheng-Kuo Chen, Hsueh-Chou Lai, Po-Heng Chuang, Ming-Hung Tsai, Wen-Pang Su, Hung-Yao Chen, Chia-Sheng Chu, Jen-Wei Chou, Sheng-Hung Chen, Tsung-Yu Tsai, Wang-De Hsiao, Chun-Che Lin, Guan-Tarn Huang, Jaw-Town Lin, Cheng-Yuan Peng
发表日期
2021
期刊
American Journal of Cancer Research
卷号
11
期号
12
页码范围
6173
出版商
e-Century Publishing Corporation
简介
Combined immune checkpoint inhibitors (ICIs) along with tyrosine kinase inhibitors (TKIs) and locoregional therapies have been used increasingly to treat hepatocellular carcinoma (HCC). Biomarkers are required to predict the treatment efficacy of ICIs with or without combination therapies in patients with unresectable HCC. This study enrolled 95 consecutive patients with unresectable HCC from May 2017 to June 2021 from two hospitals retrospectively. Of the 95 patients, 15 and 80 had Barcelona Clinic Liver Cancer stages B and C, respectively. The median ICI treatment duration was 3.43 (1.87-7.87) months, and 77 patients received combination therapies. Radiological imaging was not performed in 13 patients. Objective response and disease control rates were 27.4% and 53.7%, respectively. The duration of progression-free survival (PFS) and overall survival (OS) was 4.07 (1.59-6.54) months and 14.53 (6.93 …
学术搜索中的文章
WF Hsu, HW Wang, CK Chen, HC Lai, PH Chuang… - American Journal of Cancer Research, 2021